Literature DB >> 23623561

Surgical treatment of extraluminal pelvic recurrence from rectal cancer: oncological management and resection techniques.

P Pereira1, L Ghouti, J Blanche.   

Abstract

Local recurrence (LR) after curative surgery for rectal cancer occurs in 4 to 33% of cases especially with suboptimal surgery (non-TME). For numerous patients, diagnosis of LR is done at late stage of the disease because of the high rate of asymptomatic patients. MRI and PET-scan are the most performing exams to assess the local and general extension, with high diagnostic accuracy (sensibility 85% and specificity 92%). For extraluminal pelvic recurrences from rectal cancer, pelvic exenterations alone or with irradiation (preoperative and/or intraoperative) can afford a R0 resection rate ranging from 30% to 45% with acceptable morbidity. Morbidity and mortality rates are high for total exenteration and abdominosacral resection. After curative surgery, 5-year global survival from 30% to 40% is observed. Careful selection of patients with better preoperative status before resection is needed to achieve more curative resections and increase long-term survivor rates.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23623561     DOI: 10.1016/j.jviscsurg.2013.03.007

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  3 in total

1.  Prospective Observational Study of High-Dose Carbon-Ion Radiotherapy for Pelvic Recurrence of Rectal Cancer (GUNMA 0801).

Authors:  Shintaro Shiba; Masahiko Okamoto; Hiroki Kiyohara; Tatsuya Ohno; Takuya Kaminuma; Takayuki Asao; Hitoshi Ojima; Ken Shirabe; Hiroyuki Kuwano; Takashi Nakano
Journal:  Front Oncol       Date:  2019-07-31       Impact factor: 6.244

2.  LAPAROSCOPIC ABDOMINOPERINEAL RESECTION WITH SACRECTOMY: TECHNICAL DETAILS AND PITFALLS.

Authors:  Haroldo Jose Siqueira Igreja-Junior; Vilson Leite Batista; Bruno Dos Santos Viana Carvalho; Lucas Simões Tavares; Juliana Gonçalves Coelho
Journal:  Arq Bras Cir Dig       Date:  2017 Oct-Dec

3.  Livin serves as a prognostic marker for mid-distal rectal cancer and a target of mid-distal rectal cancer treatment.

Authors:  Qi-Biao Su; Lai-You Wang; Gui-Ning Wei; Li-Zhen Liao; Jie Zhao; Hong-Jun Liu; Yu-Long Shi; Le-Ping Li; Chen-Sheng Li
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.